Abstract: Stable oleaginous gels comprising water-in-oil emulsions in gels are disclosed. Sustained release injectable pharmaceutical formulations comprising such oleaginous gels are also disclosed, in particular such formulations comprising interferon.
Type:
Grant
Filed:
November 26, 1986
Date of Patent:
July 25, 1989
Assignee:
Schering Corporation
Inventors:
Zachary Yim, Michael A. Zupon, Imtiaz A. Chaudry
Abstract: Stable pharmaceutical compositions comprising interferon and thimerosal which are substantially resistant to microorganism contamination and growth are disclosed.
Abstract: Compositions for the transdermal delivery of azatadine and the use of such compositions in the treatment of allergic reactions are disclosed.
Abstract: Novel compounds with angiotensin-converting enzyme inhibitory activity are disclosed. Such compounds are useful in the treatment of cardiovascular disorders, especially hypertension and congestive heart failure, and are useful in the treatment of glaucoma. Also disclosed is a novel process for preparing intermediates useful in the preparation of the claimed compounds.
Type:
Grant
Filed:
September 28, 1988
Date of Patent:
May 16, 1989
Assignee:
Schering Corporation
Inventors:
Elijah H. Gold, Bernard R. Neustadt, Elizabeth M. Smith
Abstract: A method of purifying a polypeptide having a physiological activity such as one having interferon activities from a culture mixture of a microorganism obtained by a recombinant DNA technique and capable of producing the polypeptide is disclosed. The method comprises subjecting the cultured cells to extraction and purification in the presence of a salt of zinc or copper and polyethyleneimine thereby inhibiting decomposition and denaturation of the polypeptide. The extracted polypeptide can be further purified by column chromatographies using a column containing an anion exchange resin, column containing a cation exchange resin and column containing a gel filtration resin.
Type:
Grant
Filed:
October 10, 1986
Date of Patent:
May 9, 1989
Inventors:
Naoki Higashi, Shunjiro Sugimoto, Masafumi Tsujimoto, Hounai Shirasawa, Tsutomu Okada, Kazumori Yamamoto, Tattanahalli L. Nagabhushan, Paul P. Trotta
Abstract: Antihypertensive compounds with angiotensin-converting enzyme inhibitory activity and diuretic activity are disclosed. Such compounds are useful in the treatment of cardiovascular disorders, especially hypertension and congestive heart failure, and are useful in the treatment of glaucoma.
Abstract: A method of enhancing transdermal delivery of a pharmaceutically active drug from a transdermal delivery system as well as a transdermal delivery system capable of providing a desirable flow interface between the delivery system and the skin surface are disclosed. The method involves pre-treating an area of skin with an anticholinergic agent in an amount sufficient to have a local antisecretory effect on the area treated, such amount being insufficient to cause systemic effects; and applying the transdermal delivery system to the pre-treated area. The delivery system of the present invention is comprised of a carrier means, a pharmaceutically active drug and an anticholinergic agent. With both the method and the delivery system, the anticholinergic agent is preferably a quaternary ammonium salt which is itself transdermally delivered to the area beneath the delivery system in an amount sufficient to suppress perspiration in that area.
Abstract: The present invention relates to carboxyalkyl dipeptides which are inhibitors of angiotensin-converting enzyme and are useful as antihypertensive agents and in the treatment of congestive heart failure.The compounds of the present invention are compounds of the formulae ##STR1## and the pharmaceutically acceptable salts thereof, wherein R and R.sup.6 are the same or different and are hydroxy or lower alkoxy;R.sup.1 is benzyloxylower alkyl or benzylthiolower alkyl;R.sup.2 is benzylthiomethyl, 2-phyenylethylthiomethyl, napthylmethylthiomethyl, methylbenzylthiomethyl, 2-(carboxyphenyl)ethyl or 2-(alkoxycarbonylphenyl)ethyl) andR.sup.3 is hydrogen, lower alkyl or aminolower alkyl.
Type:
Grant
Filed:
November 4, 1987
Date of Patent:
April 4, 1989
Assignee:
Schering Corporation
Inventors:
Elijah H. Gold, Bernard R. Neustadt, Elizabeth M. Smith
Abstract: A method of inducing anorexia or nasal decongestion comprising transdermally administering an enantiomer of phenylpropanolamine is disclosed.
Abstract: The present invention relates to carboxyalkyl dipeptides which are inhibitors of angiotensin-converting enzyme and are useful as antihypertensive agents and in the treatment of congestive heart failure.The compounds of the present invention are compounds of the formulae ##STR1## and the pharmaceutically acceptable salts thereof, wherein R and R.sup.6 are the same or different and are hydroxy or lower alkoxy;R.sup.1 is benzyloxylower alkyl or benzylthiolower alkyl;R.sup.2 is benzylthiomethyl, 2-phenylethylthiomethyl, naphthylmethylthiomethyl, methylbenzylthiomethyl; 2-(carboxyphenyl)ethyl or 2-(alkoxycarbonylphenyl)ethyl; andR.sup.3 is hydrogen, lower alkyl or aminolower alkyl.
Type:
Grant
Filed:
March 23, 1987
Date of Patent:
February 28, 1989
Assignee:
Schering Corporation
Inventors:
Elijah H. Gold, Bernard R. Neustadt, Elizabeth M. Smith
Abstract: Novel mercapto-acylamino acids useful in the treatment of hypertension and combinations of mercapto-acylamino acids and atrial natriuretic peptides useful for treating hypertension are disclosed.
Type:
Grant
Filed:
March 27, 1987
Date of Patent:
January 31, 1989
Assignee:
Schering Corporation
Inventors:
Martin F. Haslanger, Bernard R. Neustadt, Elizabeth M. Smith
Abstract: Hydrophobic peptides having antihypertensive activity are disclosed. Also disclosed are pharmaceutical compositions comprising a hydrophobic peptide and a method of treatment of mammalian hypertension comprising administering a hydrophobic peptide to a hypertensive mammal.
Type:
Grant
Filed:
October 17, 1986
Date of Patent:
August 23, 1988
Assignee:
Schering Corporation
Inventors:
Michael F. Czarniecki, Laura L. Verbiar, Timothy Kogan
Abstract: The method of treating hypertension with neutral metalloendopeptidase (NMEP) inhibitors, NMEP inhibitors in combination with atrial peptides, and NMEP inhibitors in combination with angiotensin converting enzyme inhibitors, as well as pharmaceutical compositions therefor, are disclosed.
Type:
Grant
Filed:
June 20, 1986
Date of Patent:
June 7, 1988
Assignee:
Schering Corporation
Inventors:
Martin F. Haslanger, Edmund J. Sybertz, Jr.
Abstract: A minipellet dosage form of prednisone or prednisolone, resistant to attack by saliva but readily dissolvable in gastric juice, which comprises a mixture of prednisone or prednisolone and polyvinylpyrrolidone coated onto a nonpareil seed, and further coated with a layer of dimethylaminoethyl and methyl methacrylate copolymer.
Abstract: Controlled release solid dosage forms comprising less than about one-third of the total dosage form weight of hydroxypropylmethylcellulose USP 2910 are disclosed.
Abstract: This invention relates to 2-(heterocycloalkylthio)penems wherein the nitrogen of the heterocyclic ring is connected to the alkyl group, and to their use as antibacterial agents.
Type:
Grant
Filed:
July 2, 1984
Date of Patent:
September 1, 1987
Assignee:
Schering Corporation
Inventors:
Ashit K. Ganguly, Viyyoor M. Girijavallabhan, Patrick A. Pinto, Richard W. Versace
Abstract: (Benzothiadiazine, benzamido and benzenesulfonyl)phenyl-substituted carboxyalkyl dipeptide compounds are disclosed. Compounds of this invention are useful as antihypertensive agents.
Type:
Grant
Filed:
February 20, 1986
Date of Patent:
September 1, 1987
Assignee:
Schering Corporation
Inventors:
Ronald J. Doll, Bernard R. Neustadt, Elizabeth M. Smith, Charles V. Magatti, Elijah H. Gold